In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study
- PMID: 25490399
- PMCID: PMC4260959
- DOI: 10.1371/journal.pone.0114866
In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study
Abstract
Introduction: Natural history of chronic obstructive pulmonary disease (COPD) is punctuated by exacerbations; however, little is known about prognosis of the first-ever COPD exacerbation and variables predicting its outcomes.
Materials and methods: A population-based cohort study among COPD patients with their first-ever exacerbations requiring hospitalizations was conducted. Main outcomes were in-hospital mortality and one-year mortality after discharge. Demographics, comorbidities, medications and in-hospital events were obtained to explore outcome predictors.
Results: The cohort comprised 4204 hospitalized COPD patients, of whom 175 (4%) died during the hospitalization. In-hospital mortality was related to higher age (odds ratio [OR]: 1.05 per year; 95% confidence interval [CI]: 1.03-1.06) and Charlson comorbidity index score (OR: 1.08 per point; 95% CI: 1.01-1.15); angiotensin II receptor blockers (OR: 0.61; 95% CI: 0.38-0.98) and β blockers (OR: 0.63; 95% CI: 0.41-0.95) conferred a survival benefit. At one year after discharge, 22% (871/4029) of hospital survivors were dead. On multivariate Cox regression analysis, age and Charlson comorbidity index remained independent predictors of one-year mortality. Longer hospital stay (hazard ratio [HR] 1.01 per day; 95% CI: 1.01-1.01) and ICU admission (HR: 1.33; 95% CI: 1.03-1.73) during the hospitalization were associated with higher mortality risks. Prescription of β blockers (HR: 0.79; 95% CI: 0.67-0.93) and statins (HR: 0.66; 95% CI: 0.47-0.91) on hospital discharge were protective against one-year mortality.
Conclusions: Even the first-ever severe COPD exacerbation signifies poor prognosis in COPD patients. Comorbidities play a crucial role in determining outcomes and should be carefully assessed. Angiotensin II receptor blockers, β blockers and statins may, in theory, have dual cardiopulmonary protective properties and probably alter prognosis of COPD patients. Nevertheless, the limitations inherent to a claims database study, such as the diagnostic accuracy of COPD and its exacerbation, should be born in mind.
Conflict of interest statement
Figures
Similar articles
-
Determining prognosis in acute exacerbation of COPD.Int J Chron Obstruct Pulmon Dis. 2017 Jan 31;12:467-475. doi: 10.2147/COPD.S122382. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28203070 Free PMC article.
-
Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease.Respiration. 2013;85(1):15-26. doi: 10.1159/000342036. Epub 2012 Oct 2. Respiration. 2013. PMID: 23037178
-
Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease.Respiration. 2012;84(1):36-43. doi: 10.1159/000331224. Epub 2011 Oct 12. Respiration. 2012. PMID: 21996555
-
The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research.Sci Rep. 2015 Nov 10;5:16461. doi: 10.1038/srep16461. Sci Rep. 2015. PMID: 26553965 Free PMC article. Review.
-
Acute exacerbation of COPD: is it the "stroke of the lungs"?Int J Chron Obstruct Pulmon Dis. 2016 Jul 13;11:1579-86. doi: 10.2147/COPD.S106160. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27471380 Free PMC article. Review.
Cited by
-
Temporal trends in anxiety and depression prevalence and their association with adverse outcomes in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease in Beijing, China, from 2004 to 2020.Front Psychiatry. 2022 Oct 31;13:996451. doi: 10.3389/fpsyt.2022.996451. eCollection 2022. Front Psychiatry. 2022. PMID: 36386980 Free PMC article.
-
All-cause admissions following a first ever exacerbation-related hospitalisation in COPD.ERJ Open Res. 2023 Jan 3;9(1):00217-2022. doi: 10.1183/23120541.00217-2022. eCollection 2023 Jan. ERJ Open Res. 2023. PMID: 36605904 Free PMC article.
-
One-year mortality after severe COPD exacerbation in Bulgaria.PeerJ. 2016 Dec 13;4:e2788. doi: 10.7717/peerj.2788. eCollection 2016. PeerJ. 2016. PMID: 27994981 Free PMC article.
-
Two-year mortality in survivors of acute exacerbations of chronic obstructive pulmonary disease: A North Indian study.Lung India. 2017 Nov-Dec;34(6):511-516. doi: 10.4103/lungindia.lungindia_41_17. Lung India. 2017. PMID: 29098995 Free PMC article.
-
Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.Int J Chron Obstruct Pulmon Dis. 2022 Mar 16;17:569-578. doi: 10.2147/COPD.S344669. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35321533 Free PMC article.
References
-
- Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347–365. - PubMed
-
- Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27:397–412. - PubMed
-
- Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA (2005) Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:446–452. - PubMed
-
- Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, et al. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical